1. Figure 3 Adverse cardiovascular consequences of synthetic cannabinoids
Figure 3 | Adverse cardiovascular consequences of synthetic cannabinoids. Cardiovascular effects of potent synthetic cannabinoid receptor 1 (CB1R) agonist HU210. Intravenous administration of HU210 (0.1 mg/kg) to a rat dramatically decreases left ventricular (LV) pressure (blue trace), LV contractility (+dP/dt; green trace), and blood pressure (purple trace), and shifts pressure–volume loops to the right, indicating decreased cardiac performance. After injection of a CB1R antagonist, SR (rimonabant; 10 mg/kg), cardiac function and blood pressure largely recover within 20 mins. Reprinted with permission from Pacher, P. et al. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. Nat. Protoc. 3 (9), 1422–1434 (2008), with permission from Macmillan Publishers Limited.
Reprinted with permission from Pacher, P. et al. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. Nat. Protoc. 3 (9), 1422–1434 (2008), with permission from Macmillan Publishers Limited.
Pacher, P. et al. (2017) Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Nat. Rev. Cardiol. doi: /nrcardio